Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine–treosulfan reduced-intensity conditioning before haploidentical HSCT with post-transplant cyclophosphamide in older/frail AML patients
2025-523632-39-00Phase 2Authorised
- Sponsor
- Institut Paoli-Calmettes
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in acute myeloid leukemia (AML), sponsored by Institut Paoli-Calmettes. Primary endpoint: Progression Free Survival. Planned start Aug 2026; status: authorised.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2025-523632-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523632-39-00.